Consensus Arcutis Biotherapeutics, Inc.

Equities

ARQT

US03969K1088

Market Closed - Nasdaq Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
8.365 ^USD	-3.41%		-8.68%	+158.98%

May. 28	Johnson & Johnson Acquires Experimental Eczema Drug for $1.25 Billion	MT
May. 15	Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating	MT

Evolution of the average Target Price on Arcutis Biotherapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

6.ALeDHdo-bRNmihpH-YqR3d79WHGXM1hy2HTpLqKl_2M.aNvQfrBMHFwuwFIJluCm5O6cOTXWVCItqh2Le-WWuypm28ErvFUMQg3OSw~edcaa1eb4aaa702cd8ef39c3897e875b

Analyst Recommendations on Arcutis Biotherapeutics, Inc.

Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating	May. 15	MT
Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating	May. 15	MT
Mizuho Securities Raises Price Target on Arcutis Biotherapeutics to $17 From $16, Maintains Buy Rating	Feb. 28	MT
Needham Raises Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	Feb. 28	MT
Mizuho Increases Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	Feb. 23	MT
Mizuho Upgrades Arcutis Biotherapeutics to Buy From Neutral, Raises Price Target to $8 From $4	Jan. 03	MT
Exchange-Traded Funds Mixed; US Equities Rise Pre-Bell Monday as Investors Hope for Federal Reserve Rate Cuts Soon	Dec. 18	MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $10 From $45, Maintains Overweight Rating	Nov. 13	MT
JonesTrading Downgrades Arcutis Biotherapeutics to Hold From Buy	Nov. 08	MT
Needham Adjusts Price Target on Arcutis Biotherapeutics to $8 From $22, Maintains Buy Rating	Nov. 06	MT
Mizuho Downgrades Arcutis Biotherapeutics to Neutral From Buy	23-10-27	MT
Goldman Sachs Downgrades Arcutis Biotherapeutics to Neutral From Buy, Adjusts Price Target to $6 From $32	23-10-13	MT
Truist Securities Lowers Price Target on Arcutis Biotherapeutics to $40 From $45, Maintains Buy Rating	23-05-26	MT
Goldman Sachs Adjusts Price Target on Arcutis Biotherapeutics to $33 From $44, Maintains Buy Rating	23-05-11	MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $45 From $47, Maintains Overweight Rating	23-05-10	MT
Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $57 From $61, Maintains Buy Rating	23-05-10	MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $47 From $50, Keeps Overweight Rating	23-04-12	MT
Truist Securities Lowers Arcutis Biotherapeutics' Price Target to $45 From $50, Maintains Buy Rating	23-03-28	MT
Needham Adjusts Price Target on Arcutis Biotherapeutics to $24 From $46, Maintains Buy Rating	23-03-16	MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $50 From $51, Maintains Overweight Rating	23-03-01	MT
Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $51 From $49, Maintains Overweight Rating	22-12-13	MT
Morgan Stanley Adjusts Arcutis Biotherapeutics' Price Target to $49 from $46, Maintains Overweight Rating	22-10-04	MT
Morgan Stanley Lifts Price Target on Arcutis Biotherapeutics to $46 From $45, Reiterates Overweight Rating	22-09-27	MT
JonesTrading Assumes Arcutis Biotherapeutics at Buy with $54 Price Target	22-09-22	MT
Needham Starts Arcutis Biotherapeutics at Buy With $46 Price Target	22-09-07	MT